DelveInsight’s Artificial Pancreas Device Market Insights Report 2032 provides the current and forecast market analysis, individual leading Artificial Pancreas Device companies’ market shares, challenges, Artificial Pancreas Device Market Drivers, barriers, trends, and key market Artificial Pancreas Device companies in the market.
To read more about the latest highlights related to the Artificial Pancreas Device Market @ https://www.delveinsight.com/report-store/artificial-pancreas-device-system-market
Key Takeaways from the Artificial Pancreas Device Market Report
- In September 2024, Tandem Diabetes Care, Inc. announced that its t:slim X2 insulin pump with Control-IQ automated insulin delivery technology was cleared for use with Eli Lilly’s Lyumjev ultra-rapid acting insulin in the European Union. Strategic significance: Expands the range of insulins compatible with a leading automated insulin delivery platform in a key market.
- In June 2024, MCRA, a leading independent medical device and biologics Clinical Research Organization, announced its role in assisting CamDiab’s artificial pancreas software, CamAPS FX, in achieving US FDA clearance. Strategic significance: Reflects the growing regulatory momentum behind new automated insulin delivery software entering the US market.
- In May 2024, CamAPS FX, an artificial pancreas system developed by researchers at the University of Cambridge, was granted FDA approval for use by individuals with type 1 diabetes aged two and older, including during pregnancy. Strategic significance: Extends automated insulin delivery to very young children and pregnant patients, two populations where glucose management is especially challenging.
- The Artificial Pancreas Device market was valued at USD 334.76 million in 2024 and is projected to reach USD 1,116.86 million by 2032. Growth is anchored in the rising incidence of diabetes globally, increasing awareness and screening programs, and increased product development activities among key market players.
- The global Artificial Pancreas Device market is growing at a CAGR of 16.33% during the forecast period from 2025 to 2032.
- The principal drivers are the rising global incidence of diabetes; increasing awareness of diabetes and implementation of screening programs leading to earlier diagnosis; and increased product development activities by key players resulting in improved and more accessible artificial pancreas devices.
- The leading Artificial Pancreas Device Companies include Medtronic PLC, Insulet Corporation, Tandem Diabetes Care, Inc., Beta Bionics, Inc., BIGFOOT BIOMEDICAL, INC., CamDiab Ltd., Diabeloop SA, Ypsomed, INREDA DIABETIC B.V., and Nikkiso Co., Ltd., among others.
To know more about why North America is leading the market growth in the Artificial Pancreas Device Market, Get a snapshot @ https://www.delveinsight.com/report-store/artificial-pancreas-device-system-market
Artificial Pancreas Device Overview An artificial pancreas device is an automated system that combines an insulin pump with a continuous glucose monitor and an algorithm to regulate blood glucose levels in people with diabetes, mimicking the function of a healthy pancreas. The market spans threshold-suspended device systems and non-threshold-suspended device systems, used across hospitals & clinics, homecare settings, ambulatory surgical centers, and other care environments. As diabetes is a chronic condition requiring continuous monitoring and precise insulin administration, artificial pancreas systems offer a significant improvement in quality of life compared with traditional multiple daily injection regimens.
Artificial Pancreas Device Market Key Growth Drivers
- The rising global incidence of diabetes is a significant driver, with the International Diabetes Federation reporting approximately 537 million adults aged 20-79 living with diabetes globally in 2021, a figure projected to rise to 643 million by 2030 and 783 million by 2045.
- The type 1 diabetes population represents a core patient base, with the IDF Diabetes Atlas reporting 8.75 million people living with type 1 diabetes worldwide in 2022, of whom 1.52 million were under 20 years old.
- Hyperglycemia in pregnancy is expanding demand, with the IDF estimating approximately 21.1 million live births globally (16.7%) were affected by hyperglycemia during pregnancy in 2025, a condition where artificial pancreas devices can help manage blood sugar fluctuations with minimal manual intervention.
- Increasing awareness of diabetes and implementation of screening programs are leading to earlier diagnosis and better disease management, supporting demand for advanced technologies.
- Increased product development activity by key market players, including clinical trial results demonstrating improved time-in-range for pediatric patients, is enhancing the efficiency and accessibility of artificial pancreas devices.
Get a sneak peek at the Artificial Pancreas Device Market Dynamics @ https://www.delveinsight.com/report-store/artificial-pancreas-device-system-market
Artificial Pancreas Device Market Segment Analysis The Artificial Pancreas Device Market by Device Type (Threshold Suspended Device System and Non-Threshold Suspended Device System), End-User (Hospitals & Clinics, Homecare Settings, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
By device type, threshold-suspended device systems are expected to hold significant revenue share in 2024, given their ability to reduce the risk of hypoglycemia by automatically suspending insulin delivery when glucose levels drop to a specified threshold. These systems enhance patient autonomy by minimizing the need for constant manual monitoring, and the integration of advanced algorithms allows for more precise, personalized insulin delivery based on individual glucose patterns.
Which MedTech key players in the Artificial Pancreas Device Market are set to emerge as the trendsetter explore @ https://www.delveinsight.com/report-store/artificial-pancreas-device-system-market
Artificial Pancreas Device Market Region Analysis North America is expected to hold the largest share of the Artificial Pancreas Device market in 2024, driven by rising diabetes cases, increased government healthcare initiatives, the presence of key market players, and heightened population awareness. According to the CDC, an estimated 38.4 million people of all ages — 11.6% of the US population — had diabetes as of 2024, with 38.1 million adults aged 18 and older, or 14.7% of all US adults, affected in 2021. The National Diabetes Education Program, launched by the NIH and CDC, focuses on raising awareness about diabetes management through community-based programs that educate individuals about continuous glucose monitoring and automated insulin delivery systems. Continued regulatory approvals, including the May 2024 FDA approval of CamAPS FX for individuals with type 1 diabetes aged two and older, including during pregnancy, are expected to further propel regional market growth.
Artificial Pancreas Device Companies Medtronic PLC, Insulet Corporation, Tandem Diabetes Care, Inc., Beta Bionics, Inc., BIGFOOT BIOMEDICAL, INC., CamDiab Ltd., Diabeloop SA, Ypsomed, INREDA DIABETIC B.V., Nikkiso Co., Ltd., Pancreum, Inc., Johnson & Johnson Services, Inc., Dexcom, Inc., TypeZero Technologies, Animas Corporation, and others.
Artificial Pancreas Device Market Restraints The risk of skin irritation and other device-related discomfort, along with an increase in product recalls, may hinder growth of the Artificial Pancreas Device market.
Interested in knowing the Artificial Pancreas Device Market by 2032? Click to get a snapshot of the Artificial Pancreas Device Market Trends- https://www.delveinsight.com/report-store/artificial-pancreas-device-system-market
Scope of the Artificial Pancreas Device Market Report
- Coverage- Global
- Forecast Period- 2025-2032
- Artificial Pancreas Device Companies- Medtronic PLC, Insulet Corporation, Tandem Diabetes Care, Inc., Beta Bionics, Inc., BIGFOOT BIOMEDICAL, INC., CamDiab Ltd., Diabeloop SA, Ypsomed, INREDA DIABETIC B.V., Nikkiso Co., Ltd., and others.
- Artificial Pancreas Device Market Restraints and Regulatory Analysis
- Artificial Pancreas Device Porter Five Forces Analysis and Market Assessment
Explore more information of the Artificial Pancreas Device Market Insights @ https://www.delveinsight.com/report-store/artificial-pancreas-device-system-market
Table of Contents
- Artificial Pancreas Device Market Report Introduction
- Artificial Pancreas Device Market Executive Summary
- Competitive Landscape
- Regulatory Analysis
- Artificial Pancreas Device Market Key Factors Analysis
- Artificial Pancreas Device Market Porter’s Five Forces Analysis
- Artificial Pancreas Device Market Assessment
- Artificial Pancreas Device Devices Market Company and Product Profiles
- KOL Views
- Project Approach
- About DelveInsight
- Disclaimer & Contact Us
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
